# Safety and Efficacy Study for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia After Refractive Surgery

> **NCT01643252** · PHASE3 · WITHDRAWN · sponsor: **Glaukos Corporation**

## Conditions studied

- Corneal Ectasia

## Interventions

- **DRUG:** riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system
- **DRUG:** placebo: 0.0% riboflavin ophthalmic solution with the KXL system

## Key facts

- **NCT ID:** NCT01643252
- **Lead sponsor:** Glaukos Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-07
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study was withdrawn for business reasons.
- **Last updated:** 2021-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01643252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01643252, "Safety and Efficacy Study for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia After Refractive Surgery". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01643252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*